Ticagrelor (trade name Brilinta in the US, Brilique and Possia in the EU) is a platelet aggregation inhibitor produced by AstraZeneca. The drug was approved for use in the European Union by the European Commission on December 3, 2010. The drug was approved by the US Food and Drug Administration on July 20, 2011.
Read more about Ticagrelor: Indications, Contraindications, Adverse Effects, Physical and Chemical Properties, Pharmacokinetics, Mechanism of Action, Interactions